ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0828

Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease

Navneet Kaur1, Xianhong Xie2, Anna Korogodina3, Krystal L. Cleven4, Bibi Ayesha5 and Anand Kumthekar6, 1Touro University Medical Group, Sacramento, CA, 2Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, 3Department of Medicine, Montefiore Medical Center-Wakefield/Albert Einstein College of Medicine, Bronx, NY, 4Division of Pulmonary Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 5Montefiore Medical Center, Tarrytown, NY, 6Division of Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, interstitial lung disease, Mortality, quality of life, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue disease (CTD). The aim of our study is to evaluate the impact of hospitalization on clinical outcomes in CTD-ILD patients in a racially and ethnically diverse cohort of patients.

Methods: We queried Clinical Looking Glass (CLG) to conduct a retrospective chart review of patients >18 years of age with radiological or biopsy-proven ILD associated with rheumatologist diagnosed CTD based on ICD9/10 codes who were seen at Montefiore Medical Center between January 2007 and December 2018. Patients who had either 2 CT scans of the chest and/or 2 sets of pulmonary function tests (PFT) at least 6 months apart were included in the study. We collected dataon clinical demographics, cause of hospitalization, length of hospital stay, use of immunosuppression therapy, and mortality. The patients were stratified into 2 cohorts: non-hospitalized and hospitalized. The latter cohort was further sub-stratified into patients with cardiopulmonary vs. non-cardiopulmonary hospitalization (Figure 1). The data were analyzed using Two-sample T-tests orWilcoxon’s rank sum tests for continuous variables, and Chi-square or Fisher’s exact tests for categorical variables as appropriate. Survival analysis was done using the Kaplan-Meier method. Log-rank tests were used to compare differences between the groups. Cox regression models were used to get the hazard ratios with confidence intervals.

Results: We identified 213 patients with CTD-ILD and 96 met our inclusion criteria (Figure 1). A majority of our patients identified themselves as Black (40%) and Hispanic (54%). The most common CTD was rheumatoid arthritis (29%), followed by inflammatory myositis (22%), and systemic sclerosis (15%). The median duration that the patients had a diagnosis of ILD was 4 years (IQR 5-9 years). Hospitalization was recorded in 73 (76%) patients. Baseline characteristics were similar between the hospitalized and non-hospitalized groups (Table 1). No death was observed in the non-hospitalized group, while the risk of death was significantly higher among the hospitalized group (p-value=0.02). There were 17 patients referred for transplant evaluation and all were from the hospitalized group. When stratified by the cause for hospitalization, 51/73 (70%) had a hospitalization for a cardiopulmonary cause. They were significantly older (Mean+SD) (57.2 +13.1 years) than those admitted with non-cardiopulmonary cause (Mean+SD) (49.2+14.8 years). Older age and length of stay greater than 7 days for cardiopulmonary cause were associated with a higher risk of mortality (HR 1.95, 95% CI: 1.11-3.42, p=0.02; and HR 4.82, 95% CI: 1.37-16.92, p=0.01 respectively) (Figure 2).

Conclusion: In our cohort of patients with CTD-ILD, hospitalization for cardiopulmonary causes, especially with a length of stay exceeding 7 days was associated with increased mortality. This finding can help to identify high-risk patients during hospital admission and arrange close monitoring and multidisciplinary care after discharge.

Supporting image 1

Figure 1: Flow chart showing hospitalization pattern in CTD-ILD patients

Supporting image 2

Table 1: Baseline Characteristics of patients with CTD-ILD

Supporting image 3

Figure 2: Kaplan-Meier curve for time from the diagnosis of ILD to death vs length of stay for cardiopulmonary cause > 7 (among hospitalized patients)


Disclosures: N. Kaur, None; X. Xie, None; A. Korogodina, None; K. Cleven, None; B. Ayesha, None; A. Kumthekar, None.

To cite this abstract in AMA style:

Kaur N, Xie X, Korogodina A, Cleven K, Ayesha B, Kumthekar A. Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-hospitalization-on-clinical-outcomes-in-patients-with-connective-tissue-disease-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-hospitalization-on-clinical-outcomes-in-patients-with-connective-tissue-disease-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology